METIS TechBio

About METIS TechBio

METIS TechBio is a biotechnology company that operates at the intersection of artificial intelligence and nanomaterial science to innovate drug delivery and formulation. Founded in 2020 by a team of MIT-trained scientists, the company aims to address challenges in delivering active agents to specific targets within the body. The co-founders include CEO Dr. Chris Lai, who has a background in chemical engineering and strategic consulting, and COO Dr. Wenshou Wang, who has experience in AI and polymer synthesis from his time at MIT's CSAIL.

The company's core technology is its proprietary AI-driven platform, NanoForge, which integrates quantum chemistry, molecular dynamics simulations, and machine learning to design and optimize nanomaterials for therapeutic delivery. This platform includes three main solutions: AiLNP for designing nucleic acid delivery systems, AiRNA for optimizing mRNA sequences, and AiTEM for designing small-molecule formulations. The NanoForge platform works in a closed loop, handling molecular generation, property prediction, lab experimentation, and formulation design to accelerate the development process. For example, it reduced the preclinical formulation optimization period for its MTS-004 candidate to under three months from the industry average of one to two years.

METIS TechBio's business model involves developing its own pipeline of drug candidates while also engaging in strategic collaborations and partnerships. The company targets a wide range of diseases, including cancer, neurodegenerative conditions, and metabolic and autoimmune disorders. Its pipeline includes over 10 programs, with several candidates in preclinical and clinical stages. One significant milestone was its internally developed small-molecule candidate, MTS-004, meeting its primary endpoint in a Phase III clinical trial for Pseudobulbar Affect (PBA). The company has also established the OpenCGT platform to support the development of cell and gene therapies by addressing delivery challenges.

Since its inception, METIS TechBio has secured significant funding, including an $86 million Series A in 2021 and a $57 million (RMB 400 million) Series D in 2025. These funds are used to upgrade its platform's automation, advance its product pipeline, and expand global partnerships. The company operates with a global presence, including offices in Beijing, China, and Cambridge, Massachusetts.